Catequentinib
Catequentinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
409 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 19 | 71 | 13 | 6 | 15 | 107 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 16 | 71 | 16 | 1 | 12 | 102 |
| Small cell lung carcinoma | D055752 | — | — | 3 | 23 | 4 | 1 | 4 | 33 |
| Neoplasms | D009369 | — | C80 | 9 | 18 | 1 | 1 | 1 | 26 |
| Sarcoma | D012509 | — | — | 4 | 16 | 3 | 3 | 2 | 24 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 7 | 2 | 2 | 3 | 12 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | 6 | 2 | 2 | 3 | 11 |
| Radiotherapy | D011878 | — | — | — | 2 | — | 1 | — | 3 |
| Papillary thyroid cancer | D000077273 | — | — | — | 1 | 1 | 1 | — | 2 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | 1 | — | 2 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 7 | 46 | 8 | — | 4 | 57 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 4 | 17 | 3 | — | 4 | 24 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 16 | 1 | — | 4 | 23 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 15 | 3 | — | 4 | 22 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 14 | 1 | — | 1 | 15 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 13 | 1 | — | 1 | 14 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 10 | 2 | — | 1 | 14 |
| Adenocarcinoma | D000230 | — | — | 4 | 10 | 1 | — | 1 | 13 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 9 | 1 | — | 1 | 12 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 9 | 1 | — | 3 | 12 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 5 | 15 | — | — | — | 16 |
| Esophageal neoplasms | D004938 | — | C15 | — | 7 | — | — | 5 | 12 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 8 | — | — | — | 10 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 7 | — | — | — | 7 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 4 | — | — | 2 | 7 |
| Immunotherapy | D007167 | — | — | 1 | 5 | — | — | 1 | 6 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | 6 | — | — | — | 6 |
| Digestive system neoplasms | D004067 | — | — | 1 | 6 | — | — | — | 6 |
| Lymphoma | D008223 | — | C85.9 | — | 5 | — | — | — | 5 |
| Female genital neoplasms | D005833 | — | — | 1 | 4 | — | — | 1 | 5 |
Show 58 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chemoradiotherapy | D059248 | — | — | — | — | — | — | 1 | 1 |
| Small cell carcinoma | D018288 | — | — | — | — | — | — | 1 | 1 |
| Aggressive fibromatosis | D018222 | — | D48.11 | — | — | — | — | 1 | 1 |
| Ultrasonography | D014463 | — | — | — | — | — | — | 1 | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Catequentinib |
| INN | catequentinib |
| Description | Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1058156-90-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4303201 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | GKF8S4C432 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
148 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use